221 results on '"Poulain, Stéphanie"'
Search Results
2. Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression
3. Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
4. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
5. High frequency of clonal hematopoiesis in Erdheim-Chester disease
6. Maladie de Waldenström
7. New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
8. Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains
9. Next-CLL, a New Next-Generation Sequencing–Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid Leukemia
10. Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
11. Supplemental Table 1 Gene expression profilling from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
12. Supplementary Table 1, Supplementary Figures 1-4 from TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
13. List of pathways analyzed for GSEA from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
14. TCL1 expression patterns in Waldenström macroglobulinemia
15. How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy
16. The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots
17. Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
18. Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
19. Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider
20. MYD88 L265P mutation in Waldenstrom macroglobulinemia
21. Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes in Waldenström Macroglobulinemia
22. Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepatosplenic‐Tγδ‐cell lymphoma
23. Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains
24. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
25. Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia
26. High-Throughput Genomic Analysis in Waldenström's Macroglobulinemia
27. Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
28. Efficacy of ibrutinib in the treatment of Bing–Neel syndrome
29. Increased trisomy 12 frequency and a biased IgVH 3–21 gene usage characterize small lymphocytic lymphoma
30. Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab
31. Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepato-splenic-Tγδ-cell lymphoma
32. Next-CLL, a New Next-Generation Sequencing–Based Method for Assessment of IGHVGene Mutational Status in Chronic Lymphoid Leukemia
33. Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia
34. Lenalidomide is safe and active in Waldenström macroglobulinemia
35. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma
36. SDF1/CXCL12 (−801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia
37. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization ( FILO )
38. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia
39. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
40. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
41. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
42. Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells
43. Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia
44. Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia
45. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
46. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia
47. Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement
48. Shared clonal IGH rearrangement in BCP‐ALL occurring after CLL: pitfalls and implications for MRD monitoring
49. Expression of the multidrug resistance-associated protein in myelodysplastic syndromes
50. Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.